Amylyx Pharma: FDA Extends PDUFA Date For AMX0035 - Quick Facts

Amylyx Pharmaceuticals, Inc. (AMLX) announced the FDA has extended the review timeline of the New Drug Application for AMX0035 for the treatment of amyotrophic lateral sclerosis. The updated PDUFA goal date is September 29, 2022.

The FDA extended the PDUFA date to allow more time to review additional analyses of data from the clinical studies. The submission of the information has been determined by the FDA to constitute a major amendment to the NDA, resulting in an extension of the PDUFA goal date, the company noted.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Three experimental physicists - Alain Aspect, John F. Clauser and Anton Zeilinger - have won this year's Nobel Prize for physics for their achievements in quantum mechanics. Announcing the winners in Stockholm Tuesday, the Royal Swedish Academy of Sciences said the coveted prize was awarded to the trio "for experiments with entangled photons, establishing the violation of Bell inequalities and pi The United States has announced that it will be imposing new round of sanctions this week on perpetrators of violence against peaceful protestors in Iran. The United States is also holding accountable Iranian officials and entities such as the Morality Police, that are responsible for employing violence to suppress civil society, President Joe Biden said in a statement. Biden said he is gravel Factory Orders, Job Openings, and Labor Turnover Survey might be the major highlights on Tuesday. Fed speeches also will get attention. Early signs from the U.S. Futures Index suggest that Wall Street might open higher. Asian shares finished broadly up and European shares are progressing. As...
Follow RTT